Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Accretion Pharmaceuticals IPO is a book build issue of ₹29.75 crores. The issue is entirely a fresh issue of 0.29 crore shares of ₹29.75 crore.
Accretion Pharmaceuticals IPO bidding started from May 14, 2025 and ended on May 16, 2025. The allotment for Accretion Pharmaceuticals IPO was finalized on May 19, 2025. The shares got listed on NSE SME on May 21, 2025.
Accretion Pharmaceuticals IPO price band is set at ₹101.00 per share . The lot size for an application is 1,200. The minimum amount of investment required by an retail is ₹1,21,200 (1200 shares) (based on upper price). The minimum lot size investment for HNI is 2 lots (2,400 shares), amounting to ₹2,42,400.
Jawa Capital Services Pvt.Ltd. was the book running lead manager and Kfin Technologies Ltd. was the registrar of the issue. The market maker of the company is Gretex Share Broking Pvt.Ltd..
Refer to Accretion Pharmaceuticals IPO RHP for detailed Information.
| IPO Date | May 14, 2025 to May 16, 2025 |
| Listing Date | May 21, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹96 to ₹101 per share |
| Issue Price Final | ₹101 per share |
| Lot Size | 1,200 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Reserved for Market Maker | 1,47,600 shares Gretex Share Broking Pvt.Ltd. (aggregating up to ₹1.49 Cr) |
| Net Offered to Public | 27,98,400 shares (aggregating up to ₹28.26 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 81,70,000 shares |
| Share Holding Post Issue | 1,11,16,000 shares |
Accretion Pharmaceuticals IPO offers total 29,46,000 shares. Out of which 3,52,800 (11.98%) allocated to QIB, 1,41,600 (4.81%) allocated to QIB (Ex- Anchor), 12,22,800 (41.51%) allocated to NII, 12,22,800 (41.51%) allocated to RII and 2,11,200 (7.17%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 1,47,600 (5.01%) |
| QIB Shares Offered | 3,52,800 (11.98%) |
| − Anchor Investor Shares Offered | 2,11,200 (7.17%) |
| − QIB (Ex. Anchor) Shares Offered | 1,41,600 (4.81%) |
| NII (HNI) Shares Offered | 12,22,800 (41.51%) |
| Retail Shares Offered | 12,22,800 (41.51%) |
| Total Shares Offered | 29,46,000 (100.00%) |
Accretion Pharmaceuticals IPO raises ₹2.13 crore from anchor investors. Accretion Pharmaceuticals IPO Anchor bid date is May 13, 2025. Accretion Pharmaceuticals IPO Anchor Investors list
| Bid Date | May 13, 2025 |
| Shares Offered | 2,11,200 |
| Anchor Portion Size (In Cr.) | 2.13 |
| Anchor lock-in period end date for 50% shares (30 Days) | June 18, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | August 17, 2025 |
Accretion Pharmaceuticals IPO opens on May 14, 2025, and closes on May 16, 2025.
| IPO Open Date | Wed, May 14, 2025 |
| IPO Close Date | Fri, May 16, 2025 |
| Tentative Allotment | Mon, May 19, 2025 |
| Initiation of Refunds | Tue, May 20, 2025 |
| Credit of Shares to Demat | Tue, May 20, 2025 |
| Tentative Listing Date | Wed, May 21, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, May 16, 2025 |
Investors can bid for a minimum of 1,200 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹1,21,200 |
| Retail (Max) | 1 | 1,200 | ₹1,21,200 |
| HNI (Min) | 2 | 2,400 | ₹2,42,400 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.
The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).
The company also holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, reflecting its dedication to quality and environmental management systems.
The company's manufacturing unit is located in Ahmedabad, Sanand, Gujarat.
The company has expanded its global footprint, marking its presence in more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.
Product Portfolio and Services
As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
Competitive Strength:
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Total Income | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves and Surplus | 5.41 | 1.35 | 0.00 | 0.00 |
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
| Amount in ₹ Crore | ||||
The market capitalization of Accretion Pharmaceuticals IPO is ₹112.27 Cr.
KPI as of Sun, Mar 31, 2024.
| KPI | Values |
|---|---|
| ROE | 72.47% |
| ROCE | 36.73% |
| Debt/Equity | 2.52 |
| RoNW | 72.47% |
| PAT Margin | 11.51% |
| Price to Book Value | 7.55 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 4.74 | 6.28 |
| P/E (x) | 21.29 | 16.08 |
The Company Accretion Pharmaceuticals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Capital expenditure towards purchase of new equipment/ machineries, etc. | 2.70 |
| 2 | Capital expenditure towards upgradation of existing manufacturing facility | 4.66 |
| 3 | Repayment/prepayme nt of certain borrowings availed by the Company | 0.99 |
| 4 | Funding working capital requirements | 14.68 |
| 5 | General Corporate Purpose | 4.43 |
[Dilip Davda] APL is engaged in the marketing and manufacturing of pharma products. It is largely operating on a B2B model. Spurt in its bottom lines from FY24 raise eyebrows and concern over its sustainability. It does contract manufacturing business that has large volume but less margins. Based on its financial data, the issue appears aggressively priced. Well-informed investors may park funds for long term. Read detail review...
| Listing Date | May 21, 2025 |
| BSE Script Code | |
| NSE Symbol | ACCPL |
| ISIN | INE0T8T01010 |
| Final Issue Price | ₹101 per share |
| NSE Listing Group | ST |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹101.00 |
| Open | ₹79.00 |
| Low | ₹75.05 |
| High | ₹82.95 |
| Last Trade | ₹82.95 |
Accretion Pharmaceuticals Ltd.
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Ahmedabad, Gujarat, 382213
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: apl.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Accretion Pharmaceuticals IPO is a SME IPO of 29,46,000 equity shares of the face value of ₹10 aggregating up to ₹29.75 Crores. The issue is priced at ₹101 per share. The minimum order quantity is 1200.
The IPO opens on May 14, 2025, and closes on May 16, 2025.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Accretion Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Accretion Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Accretion Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Accretion Pharmaceuticals IPO opens on May 14, 2025 and closes on May 16, 2025.
Accretion Pharmaceuticals IPO lot size is 1200, and the minimum amount required for application is ₹1,21,200.
You can apply in Accretion Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Accretion Pharmaceuticals IPO will be done on Monday, May 19, 2025, and the allotted shares will be credited to your demat account by Tuesday, May 20, 2025. Check the Accretion Pharmaceuticals IPO allotment status.
The Accretion Pharmaceuticals IPO listing date is on Wednesday, May 21, 2025.
Useful Articles
RHP